Join our daily newsletter At The Bell to receive exclusive market insights
- An abstract evaluating ImpediMed’s (IPD) SOZO BIS technology has been accepted for poster presentation at the American College of Cardiology’s (ACC) 70th Annual Scientific Session
- The paper weighs up the technology’s effectiveness in identifying heart failure patients at risk of hospital readmission
- The company’s abstract analyses data collected during ImpediMed’s heart failure home study using the SOZO digital health platform
- The SOZO fluid analysis utilises ImpediMed’s HF-Dex heart failure index to offer an objective measure of fluid overload in heart failure patients
- The poster results will also be published online in the Journal of the American College of Cardiology Abstract Supplement before the ACC Annual Scientific Session
- ImpediMed is in the grey, last trading at 14 cents
An abstract evaluating ImpediMed’s (IPD) SOZO BIS technology has been accepted for poster presentation at the American College of Cardiology’s (ACC) 70th Annual Scientific Session.
The paper weighs up the technology’s effectiveness in identifying heart failure patients at risk of hospital readmission.
The company’s abstract, titled “Bioimpedance Spectroscopy Measurement of Ongoing Fluid Overload Post Discharge from Hospitalization for Decompensated Heart Failure,” analyses data collected during ImpediMed’s heart failure home study using the SOZO digital health platform.
ImpediMed uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.
The SOZO fluid analysis for heart failure offers an objective measure of fluid overload in heart failure patients. It utilises ImpediMed’s HF-Dex heart failure index, which measures extracellular fluid as a percentage of total body water.
Throughout the study, SOZO was used to measure each patient’s fluid status at home for 45 days, following a heart failure-related hospital stay. In the abstract, HF-Dex was used to measure fluid overload in patients after being discharged from the hospital for 48 and 72 hours, comparing those who were readmitted to the hospital for heart failure and patients who were not readmitted.
“New technologies like SOZO with HF-Dex have the potential to identify patients at high risk for readmission prior to discharge and gives healthcare professionals an opportunity to intervene with the goal of reducing readmissions,” said Dr Tom Heywood, Heart Failure Cardiologist at Scripps Health and poster co-author.
An abstract evaluating this will be presented at the American College of Cardiology (ACC) 70th Annual Scientific Session in Atlanta, Georgia, focusing on “the latest science, innovation and practice-changing updates in care.”
ImpediMed says the prestigious conference, focusing on innovation in cardiac care, is the right forum to introduce SOZO to cardiologists from the U.S. and around the world.
“Presenting data here lends important credibility to our technology and its potential to integrate into existing patient care pathways for the reduction of hospital readmissions,” said ImpediMed Managing Director and CEO, Richard Carreon.
“These results will support our commercialisation effort in heart failure, which is one of our three strategic focus areas,” he continued.
The poster results will be published online in the Journal of the American College of Cardiology Abstract Supplement before the ACC Annual Scientific Session. The conference will be a tandem forum with both physical and virtual attendance.
ImpediMed is in the grey, last trading at 14 cents at 10:17 am AEDT.
